Key Stats for Novo Nordisk Stock
- Current Price: $44.96
- Target Price (Mid): ~$73
- Street Target: $46.69
- Potential Total Return: ~63%
- Annualized IRR: ~11% / year
- Earnings Reaction: +0.09% (May 6, 2026)
- Max Drawdown: 56.46% on 3/30/26
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Novo Nordisk (NVO) spent the better part of 18 months becoming one of the most painful trades in global pharma, falling 56.46% from its peak to a max drawdown on March 30, 2026, per TIKR data. On May 22, it gave investors a reason to reconsider.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending EU marketing authorization for the Wegovy pill, once-daily oral semaglutide 25 mg, making it the first oral GLP-1 (glucagon-like peptide-1, a hormone that regulates appetite) obesity therapy in Europe. The same session produced a second win: CHMP also recommended EU approval for Wegovy 7.2 mg in a single-dose pen, a higher-dose injectable delivering up to 20.7% mean weight loss in clinical trials. NVO closed up 1.28% on May 22 at $44.96.
The EU news follows a Q1 2026 earnings report that was better than the headline numbers suggested. Total revenue missed consensus by 2.09% and adjusted EPS missed by 4.75%, per TIKR’s Beats & Misses data. The stock moved just 0.09% on the reporting day. But the Wegovy pill, which launched in the U.S. on January 5, generated around DKK 2.3 billion in its debut quarter against analyst estimates of roughly DKK 1.16 billion compiled by Reuters, nearly double Wall Street’s forecast. EBITDA beat by 7.62% and net income beat by 11.00%, per TIKR.
A Record Launch With a Clear Competitive Edge
The Wegovy pill data from Q1 addresses the market’s core fear directly.
Jamey Millar, EVP of U.S. Operations, told analysts on the May 6 call that Q1 total prescriptions reached 1.3 million, with cumulative prescriptions since launch surpassing 2 million. Weekly prescriptions for the week ending April 17 were 207,000. Close to 80% of Wegovy pill users had never tried a GLP-1 treatment before, meaning the pill is expanding the market rather than pulling patients from the injectable franchise. The cannibalization risk that weighed on NVO’s multiple for months appears, at least in early data, to have been overstated.
On pricing, CEO Maziar Doustdar was direct: “We have priced this product perfectly correct. We are seeing a situation where at the current prices, we have had 2 million scripts after 16 weeks, more than 200,000 scripts per week.” He acknowledged that prices will eventually need to fall as the company scales to a much broader patient population, but said the current price is right for where the volume curve sits today.
By the end of Q1, all three of the largest pharmacy benefit managers (PBMs, the companies that manage drug coverage on behalf of insurers) had added Wegovy pill to their standard formularies at parity with the injectable. That infrastructure positions the reimbursed channel mix to improve meaningfully in the second half of 2026.
See historical and forward estimates for Novo Nordisk stock (It’s free!) >>>
What the EU Win Means Commercially
The CHMP opinion requires formal European Commission sign-off, typically within two months, before it becomes binding. Novo plans to launch the Wegovy pill in select markets outside the U.S. in the second half of 2026, pending that final step.
The EU label is competitively strong. Per Novo Nordisk’s CHMP announcement, the Wegovy pill demonstrated 16.6% mean weight loss in the OASIS 4 trial, with one in three patients achieving 20% or greater weight loss. The label includes SELECT cardiovascular outcomes data showing a reduction in major adverse cardiovascular events (heart attack, stroke, and cardiovascular death). It carries no drug-drug interaction restrictions, which management flagged as a key differentiator.
Eli Lilly (LLY) launched Foundayo, its own oral obesity pill, in the U.S. in early April 2026. Early prescription data showed Foundayo lagging the Wegovy pill significantly in the comparable launch window. On valuation multiples, the gap between the two companies is stark. Per TIKR’s Competitors page as of 5/22/26, NVO trades at an NTM EV/EBITDA of 9.85x and an NTM P/E of 13.13x. Eli Lilly trades at 22.58x NTM EV/EBITDA and 28.63x NTM P/E. Roche sits at 11.15x NTM EV/EBITDA and 16.32x NTM P/E. NVO is the cheapest name in the peer group by a wide margin, a discount that reflects investor skepticism rather than any structural impairment of the underlying business.
Internationally, EVP Emil Larsen told analysts that Q1 international obesity care sales grew 44% to DKK 9.2 billion. Novo holds approximately 55% weekly injectable GLP-1 volume market share across international markets, and Larsen said share losses were beginning to stabilize. In some of Novo’s largest international markets, around 20% of Wegovy sales now flow through telehealth channels, a distribution shift that lowers traditional promotional costs while maintaining reach.
A Pipeline the Stock Price Is Not Reflecting
Chief Scientific Officer Martin Holst Lange outlined several near-term catalysts on the Q1 call. CagriSema, the combination of semaglutide and cagrilintide that fell short of demonstrating superiority over Eli Lilly’s tirzepatide (a rival dual-hormone obesity drug) in the February REDEFINE 4 trial, still has a U.S. regulatory decision expected by year-end, with a potential launch in 2027 pending FDA review. The AMAZE Phase III program for zenagamtide (amycretin), Novo’s next-generation oral and injectable obesity candidate, has already initiated seven trials. Lange told analysts flexible dosing protocols directly address the patient management issues that limited CagriSema’s outcomes in earlier trials, and said titration data from the reformulated REDEFINE 11 study was already showing a “substantial impact.”
Beyond obesity, Etavopivat met both co-primary endpoints in the HIBISCUS Phase III sickle cell disease trial. Sickle cell disease is an inherited condition where abnormally shaped blood cells block vessels, causing episodes of severe pain known as vaso-occlusive crises (VOCs). Etavopivat reduced VOC rates by 27% versus placebo and drove a hemoglobin response in 48.7% of patients compared to 7.2% with placebo. Novo plans to file for U.S. regulatory approval in Q4 2026. CEO Doustdar summed up the strategy plainly: “The main aim is to make sure we have multiple legs to stand on so we can drive growth short, medium and long term.”
See how Novo Nordisk performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $44.96
- Target Price (Mid): ~$73
- Potential Total Return: ~63%
- Annualized IRR: ~11% / year
See analysts’ growth forecasts and price targets for Novo Nordisk stock (It’s free!) >>>
The TIKR mid-case model targets approximately $73 by 12/31/30, using a revenue CAGR of around 6% through the forecast period. The two primary drivers are global oral Wegovy scaling as the reimbursed mix improves and international markets open, and a potential CagriSema contribution following an expected 2027 U.S. launch. The margin driver is operating leverage as the free cash flow profile recovers alongside reimbursed GLP-1 volume growth, supporting a mid-case net income margin of around 33%. That 6% forward CAGR is conservative relative to Novo’s 10-year historical revenue growth rate of 11.1%, per TIKR’s valuation model data, appropriately reflecting pricing headwinds and semaglutide loss of exclusivity in certain markets.
If the oral Wegovy rollout outperforms globally and CagriSema captures meaningful share, the high case targets around $131 by 12/31/30 at an IRR of around 13%. If pricing erosion from the Most-Favored-Nations agreement with the U.S. administration accelerates and international uptake disappoints, the low case still targets around $87 at an IRR of around 8%. Even the downside implies material total return from today’s price, a direct reflection of how far NVO has already fallen.
The Street currently carries a mean target of $46.69, per TIKR, with 4 Buys, 1 Outperform, and 9 Holds across 14 estimates. The consensus is cautious. That gap between Street hesitation and the TIKR mid-case is where the opportunity or the trap lives.
Conclusion
The EU CHMP opinion is one more data point in a recovery sequence that either compounds into a re-rating or stalls at the first sign of execution risk. The clearest test arrives August 5, when Novo reports Q2 earnings. The metric that matters most is not total prescription volume but titration rates at the 9 mg and 25 mg Wegovy pill doses, which translate directly into revenue per patient as the reimbursed mix grows. If weekly TRxs hold above 200,000 while the channel mix visibly improves, the volume-over-price thesis becomes credible.
Watch also for the Q3 ZEUS trial readout on Ziltivekimab, Novo’s anti-IL-6 compound targeting cardiovascular inflammation in patients with atherosclerotic cardiovascular disease and chronic kidney disease. A clean result adds a cardiovascular franchise to a company that the market currently values almost entirely on obesity. That combination, sustained pill uptake plus a cardiovascular catalyst, is the multi-leg growth story CEO Doustdar has been building toward. A miss on either resets the timeline materially.
The floor may be in. Q2 will tell us whether it holds.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Novo Nordisk?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Novo Nordisk, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Novo Nordisk alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Novo Nordisk on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
